-
Biotin-tyramide: Amplifying Sensitivity in IHC and ISH Workf
2026-05-22
Biotin-tyramide unlocks ultra-sensitive detection in both immunohistochemistry and in situ hybridization by harnessing enzyme-mediated signal amplification. This reagent, supplied by APExBIO, enables researchers to visualize low-abundance targets with precision, even in challenging tissue contexts.
-
Entinostat (MS-275): Precision HDAC1/3 Inhibition in Cancer
2026-05-22
Entinostat (MS-275) stands out as a selective, orally available HDAC1/3 inhibitor, empowering cancer researchers with robust tools for both in vitro and in vivo studies. This article delivers actionable workflows, protocol optimization, and troubleshooting rooted in the latest regenerative and oncology research.
-
MDV3100 (Enzalutamide): Atomic Insights for Prostate Cancer
2026-05-21
MDV3100 (Enzalutamide) is a second-generation androgen receptor antagonist used to study and modulate androgen signaling in prostate cancer models. It demonstrates high potency in inhibiting AR nuclear translocation and inducing apoptosis in AR-amplified prostate cancer cells. Robust preclinical and clinical data support its role in dissecting castration-resistant mechanisms.
-
Gemcitabine HCl in Preclinical Oncology: Mechanisms and Mode
2026-05-21
Explore the multifaceted role of Gemcitabine HCl in preclinical cancer research, focusing on its DNA replication inhibition, apoptosis induction, and model-driven insights. This article offers a deep dive into assay design and translational strategies, building upon—but distinctly expanding—current literature.
-
Pepstatin A: Applied Aspartic Protease Inhibitor Workflows
2026-05-20
Unlock the full potential of Pepstatin A as a precision aspartic protease inhibitor in viral protein processing, osteoclast differentiation, and advanced cell biology. Discover robust experimental protocols, troubleshooting insights, and nuanced workflow enhancements that set APExBIO’s Pepstatin A apart for reliability and reproducibility.
-
SERCA Inhibition with BHQ: Rethinking Stem Cell Mobilization
2026-05-20
This thought-leadership article dissects the mechanistic role of 2,5-di-tert-butylbenzene-1,4-diol (BHQ) in disrupting calcium homeostasis to facilitate hematopoietic stem cell (HSC) mobilization. By integrating recent mechanistic findings, workflow guidance, and a strategic perspective, we equip translational researchers with actionable insights beyond standard product descriptions—positioning APExBIO’s BHQ as a pivotal tool for next-generation investigations in stem cell therapy and calcium signaling research.
-
Rotenone: Applied Protocols for Mitochondrial Complex I Inhi
2026-05-19
Rotenone, a gold-standard mitochondrial Complex I inhibitor, empowers researchers to model oxidative stress, apoptosis, and neurodegeneration with unmatched specificity. By integrating recent breakthroughs and protocol refinements, this guide helps you maximize the reliability and translational relevance of your experimental designs.
-
Entinostat (MS-275): Applied Workflows for Cancer Research
2026-05-19
Entinostat (MS-275) enables selective HDAC1/3 inhibition, making it a powerful tool for dissecting cancer epigenetics and advancing anti-tumor studies. This guide delivers actionable protocols, troubleshooting insights, and best practices to maximize data fidelity in both in vitro and translational workflows.
-
CA-074: Cathepsin B Inhibitor for Advanced Necroptosis Resea
2026-05-18
CA-074 stands out as a highly selective cathepsin B inhibitor, enabling precise modulation of necroptosis, cancer metastasis, and neurotoxicity in applied research. This article dissects evidence-driven workflows and troubleshooting strategies that maximize reproducibility and translational insight with CA-074.
-
Phillygenin Attenuates Diabetic Nephropathy via Key Inflamma
2026-05-18
This study demonstrates that phillygenin, a bioactive compound from Forsythia suspensa, significantly improves diabetic nephropathy by targeting the TLR4/MyD88/NF-κB and PI3K/AKT/GSK3β pathways. The findings provide mechanistic insight into phillygenin's anti-inflammatory and anti-apoptotic actions, supporting its potential as a novel therapeutic agent for diabetic kidney injury.
-
Vasopressin Analogues: Multitasking Peptides in Endocrine an
2026-05-17
This review synthesizes current advances in vasopressin and its analogues, focusing on their multifaceted roles from endocrine regulation to emerging antiviral applications. The paper highlights how peptide modifications, such as in lypressin acetate, expand therapeutic and research potential while addressing pharmacokinetic limitations.
-
SB 431542: ALK5 Inhibitor Protocols for EVT and Immune Assay
2026-05-16
SB 431542 empowers researchers to precisely inhibit the TGF-β pathway, enabling mechanistic dissection of cell interactions in immunology and oncology. This guide translates recent advances—including novel EVT purification protocols—into actionable workflows, troubleshooting, and comparative insights.
-
5-HT3 Antagonists Inhibit Renal OCT2 and MATE1: In Vitro Evi
2026-05-15
This study systematically evaluates the in vitro inhibitory effects of five 5-HT3 receptor antagonists, including tropisetron, on renal organic cation transporters OCT2 and MATE1. The findings reveal differential potencies among these agents and highlight the potential for drug-drug interactions at the level of renal secretion, informing both pharmacological research and the safe use of antiemetic drugs.
-
Structure-Based Discovery of NSP15 Inhibitors for SARS-CoV-2
2026-05-15
This article reviews a structure-based virtual screening study that identified thymopentin and oleuropein as potent natural product inhibitors of the SARS-CoV-2 NSP15 endoribonuclease. The findings underscore the value of computational drug discovery for antiviral target validation and inform future approaches to targeting viral immune evasion mechanisms.
-
MLKL Polymerization Drives Lysosomal Disruption in Necroptos
2026-05-14
This study elucidates how MLKL polymerization, following necroptosis induction, directly triggers lysosomal membrane permeabilization (LMP), leading to cathepsin B release and cell death. These findings clarify the mechanistic link between MLKL activity, lysosomal disruption, and regulated necroptotic pathways, providing new insight for targeted intervention in cell death-associated diseases.